• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

    1.545 +0.165 (+11.96%)
    Streaming Delayed Price Updated: 3:58 PM EST, Dec 4, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Prelude Therapeutics Incorporated - Common Stock

    < Previous 1 2 Next >
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Prelude Therapeutics Announces Strategic Business Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Citizens Life Sciences Conference
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Announces Presentations at 2025 AACR Annual Meeting
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
    PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST) 
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
    From Prelude Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.